-- Suzhou Ribo Life Science (HKG:6938) achieved another milestone under a research collaboration with Boehringer Ingelheim to discover novel therapies for liver disease, according to a Hong Kong bourse filing Wednesday.
The companies are researching therapies for metabolic dysfunction-associated steatohepatitis, or MASH, a serious and progressive form of fatty liver disease.
The milestone underscores the commercial potential of Ribo Life Science's siRNA platform, the firm said.
Pangrim (KRX:003610) plans to retire about 4.09 million treasury shares, valued at 23.9 billion won, according to a Wednesday filing with the Korea Exchange.The shares will be retired on May 20 at a par value of 500 won apiece.Shares of the textile manufacturer fell more than 2% in recent trade.
Great Eastern's (SGX:G07) profit attributable to shareholders remained relatively unchanged during the first quarter of the year from a year earlier, according to a Wednesday filing with the Singapore Exchange.The attributable profit came in at SG$346.3 million, versus SG$345.5 million in the year-ago period.Total weighted new sales surged 16% year over year to SG$401.9 million in the three months ended March 31, from SG$345.1 million, backed by sustained momentum from Singapore operations.
Metallium (ASX:MTM) secured contracts covering 50% of its first-stage throughput target of 8,000 tonnes per year of printed circuit board feedstock for US operations, according to a Wednesday filing with the Australian bourse.The company is targeting a contracted base of roughly 70% of the first-stage target, while retaining about 30% exposure to spot market procurement, the filing said.Meanwhile, commissioning at the company's Texas Technology Campus is currently underway, per the filing.Metallium shares fell 1% in midday trade on Wednesday.